In both the Medicare and Medicare–Medicaid dual enrollees, roughly thirteen percent of those using an acetylcholinesterase inhibitor also consumed a mechanistically antagonistic anticholinergic for overactive bladder. The gene discussed is ACHE; the disease is overactive bladder.